阻塞性睡眠呼吸暂停和心力衰竭之间的关系的最新进展:叙述性综述
Yi Shi1, Di Deng2, Ningying Song3
1General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, China.
Sleep & breathing = Schlaf & Atmung
|November 25, 2024
概括
阻塞性睡眠呼吸暂停 (OSA) 显著增加心力衰竭 (HF) 的风险,并可能使现有的情况恶化. 像CPAP这样的治疗可能会使患者受益,但需要进一步的研究,以便在患有OSA和HF的人群中获得有效的治疗方法.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 睡眠医学 睡眠医学
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 是心血管疾病的一个已知的危险因素.
- 心力衰竭 (HF) 是一种严重的疾病,具有显著的发病率和死亡率.
- OSA和HF之间的联系需要更深入地了解它们的相互作用.
研究的目的:
- 审查OSA对HF发展和进展的影响.
- 确定OSA和HF之间共享的风险因素和病理生理机制.
- 评估当前和潜在的治疗策略,以治疗HF患者的OSA.
主要方法:
- 在PubMed/MEDLINE的综合文献搜索到2024年9月.
- 包括关于OSA,HF,它们的危险因素和治疗结果的研究.
- 专注于OSA和HF预后和管理之间的关系.
主要成果:
- OSA显然增加了发展和加剧HF的风险.
- 持续正气道压力 (CPAP) 和其他干预措施对患有OSA的HF患者显示出潜在的益处.
- 对OSA的药理疗法有希望,但大规模试验至关重要.
结论:
- 通过各种机制,OSA通过各种机制显著促进HF的发病和复发.
- 为了开发和验证并发性OSA和HF的有效治疗方法,进一步的研究是至关重要的.
相关概念视频
Sleep Apnea
128
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
128
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Mitral Regurgitation I: Introduction
4
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
4
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316


